217 related articles for article (PubMed ID: 28590426)
1. Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.
Dey N; Krie A; Klein J; Williams K; McMillan A; Elsey R; Sun Y; Williams C; De P; Leyland-Jones B
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28590426
[TBL] [Abstract][Full Text] [Related]
2. Pattern of malignant disorders in individuals with Down's syndrome.
Hasle H
Lancet Oncol; 2001 Jul; 2(7):429-36. PubMed ID: 11905737
[TBL] [Abstract][Full Text] [Related]
3. Risks of leukaemia and solid tumours in individuals with Down's syndrome.
Hasle H; Clemmensen IH; Mikkelsen M
Lancet; 2000 Jan; 355(9199):165-9. PubMed ID: 10675114
[TBL] [Abstract][Full Text] [Related]
4. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
[TBL] [Abstract][Full Text] [Related]
5. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Zhou N; Liu C; Hou H; Zhang C; Liu D; Wang G; Liu K; Zhu J; Lv H; Li T; Zhang X
Oncotarget; 2016 Nov; 7(44):72373-72379. PubMed ID: 27738308
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 21-Encoded microRNAs (mRNAs): Impact on Down's Syndrome and Trisomy-21 Linked Disease.
Alexandrov PN; Percy ME; Lukiw WJ
Cell Mol Neurobiol; 2018 Apr; 38(3):769-774. PubMed ID: 28687876
[TBL] [Abstract][Full Text] [Related]
7. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome.
De Vita S; Canzonetta C; Mulligan C; Delom F; Groet J; Baldo C; Vanes L; Dagna-Bricarelli F; Hoischen A; Veltman J; Fisher EM; Tybulewicz VL; Nizetic D
Oncogene; 2010 Nov; 29(46):6102-14. PubMed ID: 20697343
[TBL] [Abstract][Full Text] [Related]
8. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
10. Solid malignancies in individuals with Down syndrome: a case presentation and literature review.
Bratman SV; Horst KC; Carlson RW; Kapp DS
J Natl Compr Canc Netw; 2014 Nov; 12(11):1537-45. PubMed ID: 25361800
[TBL] [Abstract][Full Text] [Related]
11. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
[TBL] [Abstract][Full Text] [Related]
12. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
13. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.
Reynolds LE; Watson AR; Baker M; Jones TA; D'Amico G; Robinson SD; Joffre C; Garrido-Urbani S; Rodriguez-Manzaneque JC; Martino-Echarri E; Aurrand-Lions M; Sheer D; Dagna-Bricarelli F; Nizetic D; McCabe CJ; Turnell AS; Kermorgant S; Imhof BA; Adams R; Fisher EM; Tybulewicz VL; Hart IR; Hodivala-Dilke KM
Nature; 2010 Jun; 465(7299):813-7. PubMed ID: 20535211
[TBL] [Abstract][Full Text] [Related]
14. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
[TBL] [Abstract][Full Text] [Related]
15. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
16. Partial trisomy 21 map: Ten cases further supporting the highly restricted Down syndrome critical region (HR-DSCR) on human chromosome 21.
Pelleri MC; Cicchini E; Petersen MB; Tranebjaerg L; Mattina T; Magini P; Antonaros F; Caracausi M; Vitale L; Locatelli C; Seri M; Strippoli P; Piovesan A; Cocchi G
Mol Genet Genomic Med; 2019 Aug; 7(8):e797. PubMed ID: 31237416
[TBL] [Abstract][Full Text] [Related]
17. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
18. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
20. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
